Summer is a good time to review investment activity for pharmaceutical and biotech companies in the year so far and a new report shows that there’s still life for life science IPOs.
{iframe}http://medcitynews.com/2016/08/life-science-ipos-1h-2016-fall-investors-shy-away-risk/?utm_source=hs_email&utm_medium=email&utm_content=33509792&_hsenc=p2ANqtz–98yf51AvigD2RyrRXVeq3vWIHBpLTAsJtWIDlSb-pvQxioux0llkeSZibfE0hGjA9D2eUswjcGUGDBPaWaQsM1oqYzQ&_hsmi=33509792{/iframe}